Search
ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart
CEO Aron Knickerbocker walks us through the data, which included a doublet regimen with aldesleukin and a triplet that also included nivolumab, and suggests that Aulos is planning to meet with FDA about a potential accelerated approval pathway for the therapy.
May 31
Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.
Nov 8, 2025
SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody
He describes the safety and preliminary efficacy they have seen, including how patients are experiencing a lowering of Tregs. Plus, the...
Nov 9, 2024
Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24
Aron Knickerbocker describes the benefits of focusing on the CD-25 binding portion of IL-2 and discusses some data presented at ASCO. He...
Jun 2, 2024
.png){kind=logo}
